keyword
MENU ▼
Read by QxMD icon Read
search

Complera

keyword
https://www.readbyqxmd.com/read/26001757/emtricitabine-rilpivirine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-infection-in-adults
#1
REVIEW
Wissam K Kabbara, Wijdan H Ramadan
This paper reviews the current literature and information on the combination drug Complera(™) (rilpivirine/emtricitabine/tenofovir disoproxil fumarate) that was approved by the Food and Drug Administration (FDA) in August 2011. PubMed, Cochrane and Embase (2001-2014) were searched for primary and review articles on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate, individually or in combination. Data from drug manufacturer and product label was also used. Clinical trial reports were selected, extracted and analyzed to include relevant and recent ones...
September 2015: Journal of Infection and Public Health
https://www.readbyqxmd.com/read/25352394/emtricitabine-rilpivirine-tenofovir-disoproxil-fumarate-single-tablet-regimen-a-review-of-its-use-in-hiv-infection
#2
REVIEW
Emma D Deeks
The nucleos(t)ide reverse transcriptase inhibitors, emtricitabine and tenofovir disoproxil fumarate (tenofovir DF), and the non-nucleoside reverse transcriptase inhibitor, rilpivirine, are now available as a fixed-dose single-tablet regimen (emtricitabine/rilpivirine/tenofovir DF; Complera(®), Eviplera(®)) for the treatment of adults infected with HIV-1. In treatment-naïve adults, once-daily emtricitabine/rilpivirine/tenofovir DF was noninferior to once-daily emtricitabine/efavirenz/tenofovir DF with regard to establishing virological suppression over 96 weeks of therapy in a randomized, open-label, phase IIIb study (STaR)...
November 2014: Drugs
https://www.readbyqxmd.com/read/24308712/rilpivirine-drug-profile-of-a-second-generation-non-nucleoside-reverse-transcriptase-hiv-inhibitor
#3
REVIEW
Diego Ripamonti, Enrico Bombana, Marco Rizzi
Rilpivirine (RPV) is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) of the diarylpyrimidine family. RPV can be given once daily, is well absorbed and should be administered with food. It is eliminated mainly by hepatic metabolism. Two phase III noninferiority trials (ECHO and THRIVE), compared RPV 25mg with efavirenz (EFV) 600 mg, both given once daily, and combined with 2NRTI backbone. At week 48, response rate for pooled data were 84 versus 82% (difference: 2%; 95% CI: -2.0 to 6...
January 2014: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/23778174/complera-for-the-treatment-of-hiv
#4
Jennifer M Belavic
No abstract text is available yet for this article.
July 10, 2013: Nurse Practitioner
https://www.readbyqxmd.com/read/23681436/clinical-perspective-on-drug-drug-interactions-with-the-non-nucleoside-reverse-transcriptase-inhibitor-rilpivirine
#5
REVIEW
Herta Crauwels, Rolf P G van Heeswijk, Marita Stevens, Annemie Buelens, Simon Vanveggel, Katia Boven, Richard Hoetelmans
Rilpivirine (TMC278) is a non-nucleoside reverse transcriptase inhibitor approved in combination with other antiretrovirals for the treatment of HIV-1 infection in treatment-naive adults (Edurant(®) 25 mg once daily; Complera(®) [USA]/Eviplera(®) [EU] once daily single-tablet regimen). Rilpivirine should be administered with a meal to optimize bioavailability. Its solubility is pH dependent. Rilpivirine is primarily excreted via the feces with negligible renal elimination. Rilpivirine is predominantly metabolized by cytochrome P450 3A4...
April 2013: AIDS Reviews
https://www.readbyqxmd.com/read/22770811/antiviral-drug-advances-in-the-treatment-of-human-immunodeficiency-virus-hiv-and-chronic-hepatitis-c-virus-hcv
#6
REVIEW
Colleen M Wegzyn, David L Wyles
Antiviral therapy is recommended for all HIV infected individuals. Therefore, there is a continuous need for improvement and optimization of current therapy and the development of novel agents and drug classes. Fixed dose combinations (FDC) with the advantage of once daily dosing and improved tolerability and toxicity profiles are attractive options. The non-nucleoside reverse transcriptase inhibitor (NNRTI) based FDC of rilpivirine plus tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) (Complera(®)) and an extended release version of the NNRTI nevirapine, (Viramune XR(®)) were recent additions to the HIV armamentarium...
October 2012: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/22567823/rilpivirine-and-complera-new-first-line-treatment-options
#7
Reilly O'Neal
Two antiretroviral medicines recently came on the scene for people starting HIV treatment for the first time: Rilpivirine (brand name Edurant) won marketing approval in May, and the following August saw approval of Complera, a single-pill once-daily regimen that joins rilpivirine with two other drugs. This article explains the science behind rilpivirine and Complera and how these drugs measure up to the commonly prescribed efavirenz (Sustiva) and Atripla. lines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, published by the U...
October 2011: BETA Bulletin of Experimental Treatments for AIDS: a Publication of the San Francisco AIDS Foundation
https://www.readbyqxmd.com/read/22504027/where-rilpivirine-meets-with-tenofovir-the-start-of-a-new-anti-hiv-drug-combination-era
#8
REVIEW
Erik De Clercq
The triple-drug once-daily combination pill containing tenofovir, emtricitabine and rilpivirine for HIV treatment was launched in 2011, both in the USA (Complera) and the E.U. (Eviplera). The active ingredients of Complera or Eviplera are the nucleotide reverse transcriptase inhibitor (NtRTI) tenofovir, the nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine, and the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine. Rilpivirine originated from a collaborative research I had started with Dr...
August 1, 2012: Biochemical Pharmacology
https://www.readbyqxmd.com/read/22164521/fda-notifications-complera-approved
#9
(no author information available yet)
No abstract text is available yet for this article.
November 2011: AIDS Alert
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"